HIK — Hikma Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- £4.25bn
- £5.04bn
- $2.88bn
- 82
- 47
- 79
- 82
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 491 | 558 | 544 | 233 | 281 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 34 | 84 | 108 | 112 | 117 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -152 | -269 | -159 | -187 | -49 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 472 | 464 | 638 | 530 | 608 |
Capital Expenditures | -186 | -224 | -229 | -225 | -204 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 35 | -59 | -9 | -382 | -129 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -151 | -283 | -238 | -607 | -333 |
Financing Cash Flow Items | -48 | -34 | -53 | -77 | -97 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -155 | -298 | -287 | -58 | -337 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 166 | -119 | 103 | -156 | -65 |